Immunokinetics of a single dose of thymopoietin pentapeptide.
14 patients with classical or definite rheumatoid arthritis and a low number of E-rosette forming cells were given single doses of 5 mg and 50 mg of thymopoietin intravenously. Thymopoietin pentapeptide produced a dose-related sustained increase in E-rosette forming lymphocytes as shown by the decrease of thymopoietin dependent rosetting ratio. A single dose of 50 mg restored the number of E-rosette forming cells to normal after 12 h and this effect lasted 60 to 7 days. With the administration of 5 E-rosette forming cells markedly increased after 12 h and returned to the pretreatment level on the 2nd day. These immunokinetic data clarify some aspects of the clinical pharmacology of thymopoietin pentapeptide and must be considered for a rational schedule of treatment with the drug.
D000328:Adult; D005260:Female; D006801:Humans; D007109:Immunity / Q000187:drug effects*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology*; D012397:Rosette Formation; D013256:Steroids / Q000494:pharmacology; D016305:Thymopentin; D013946:Thymopoietins / Q000494:pharmacology*; D013951:Thymus Hormones / Q000494:pharmacology*
D010446:Peptide Fragments; D013256:Steroids; D013946:Thymopoietins; D013951:Thymus Hormones; D010396:Penicillamine; D016305:Thymopentin